Checkpoint blockade in unresectable pleural mesothelioma: Event horizon for multimodal therapy

R. Taylor Ripley; Aaron S. Mansfield; Boris Sepesi; Raphael Bueno; Bryan M. Burt

doi:10.1016/j.jtcvs.2022.01.020

Checkpoint blockade in unresectable pleural mesothelioma: Event horizon for multimodal therapy

R. Taylor Ripley, Aaron S. Mansfield, Boris Sepesi, Raphael Bueno, Bryan M. Burt

Thoracic & Cardiovascular Surgery

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	364-368
Number of pages	5
Journal	Journal of Thoracic and Cardiovascular Surgery
Volume	165
Issue number	1
DOIs	https://doi.org/10.1016/j.jtcvs.2022.01.020
State	Published - Jan 2023

Keywords

checkpoint blockade
checkpoint inhibitor
immunotherapy
ipilimumab
mesothelioma
nivolumab
pleura

ASJC Scopus subject areas

Surgery
Pulmonary and Respiratory Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jtcvs.2022.01.020

Cite this

@article{271aa1b5078f4fcda8d8b3b93c1cc841,

title = "Checkpoint blockade in unresectable pleural mesothelioma: Event horizon for multimodal therapy",

keywords = "checkpoint blockade, checkpoint inhibitor, immunotherapy, ipilimumab, mesothelioma, nivolumab, pleura",

author = "Ripley, {R. Taylor} and Mansfield, {Aaron S.} and Boris Sepesi and Raphael Bueno and Burt, {Bryan M.}",

note = "Funding Information: R.T.R. reports research support from the National Institutes of Health and the American Association for Thoracic Surgery; nonremunerated board of director of the Mesothelioma Applied Research Foundation; and was retained to provide expert opinion. A.S.M. reports research support from Novartis and Verily; remuneration to his institution for participation on advisory boards for AbbVie, AstraZeneca, Bristol Myers Squibb, Genentech, and Janssen; travel support and payment from Shanghai Roche Pharmaceuticals Ltd; and is a nonremunerated director of the Mesothelioma Applied Research Foundation. B.S. has received consultant fees from Bristol Myers Squibb and speaker fees from AstraZeneca. R.B. reports research funding from the National Institutes of Health, Intuitive Surgical Foundation, Roche, Genentech, Merck, Siemens, Verastem, Gritstone, North-Pond, and Epizyme; has served as a consultant to Regeneron and on the scientific advisory board of Novocure, has equity interests in Navigation Sciences, and intellectual property interests through Brigham and Women's Hospital. B.M.B. reports research funding from the National Institutes of Health, Cancer Prevention Research Institute of Texas, and Momotaro Gene; clinical trial funding from AstraZeneca, Novartis, and Momotaro Gene; has been a consultant for AstraZeneca, is a proctor for Intuitive Surgical, and has intellectual property and equity interests in a start-up surgical device company, Bayou Surgical. Funding Information: R.T.R. reports research support from the National Institutes of Health and the American Association for Thoracic Surgery ; nonremunerated board of director of the Mesothelioma Applied Research Foundation; and was retained to provide expert opinion. A.S.M. reports research support from Novartis and Verily ; remuneration to his institution for participation on advisory boards for AbbVie, AstraZeneca, Bristol Myers Squibb, Genentech, and Janssen; travel support and payment from Shanghai Roche Pharmaceuticals Ltd ; and is a nonremunerated director of the Mesothelioma Applied Research Foundation. B.S. has received consultant fees from Bristol Myers Squibb and speaker fees from AstraZeneca. R.B. reports research funding from the National Institutes of Health , Intuitive Surgical Foundation , Roche , Genentech , Merck , Siemens , Verastem , Gritstone , North-Pond , and Epizyme ; has served as a consultant to Regeneron and on the scientific advisory board of Novocure, has equity interests in Navigation Sciences, and intellectual property interests through Brigham and Women's Hospital. B.M.B. reports research funding from the National Institutes of Health , Cancer Prevention Research Institute of Texas , and Momotaro Gene ; clinical trial funding from AstraZeneca , Novartis , and Momotaro Gene ; has been a consultant for AstraZeneca, is a proctor for Intuitive Surgical, and has intellectual property and equity interests in a start-up surgical device company, Bayou Surgical. ",

year = "2023",

month = jan,

doi = "10.1016/j.jtcvs.2022.01.020",

language = "English (US)",

volume = "165",

pages = "364--368",

journal = "Journal of Thoracic and Cardiovascular Surgery",

issn = "0022-5223",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Checkpoint blockade in unresectable pleural mesothelioma

T2 - Event horizon for multimodal therapy

AU - Ripley, R. Taylor

AU - Mansfield, Aaron S.

AU - Sepesi, Boris

AU - Bueno, Raphael

AU - Burt, Bryan M.

N1 - Funding Information: R.T.R. reports research support from the National Institutes of Health and the American Association for Thoracic Surgery; nonremunerated board of director of the Mesothelioma Applied Research Foundation; and was retained to provide expert opinion. A.S.M. reports research support from Novartis and Verily; remuneration to his institution for participation on advisory boards for AbbVie, AstraZeneca, Bristol Myers Squibb, Genentech, and Janssen; travel support and payment from Shanghai Roche Pharmaceuticals Ltd; and is a nonremunerated director of the Mesothelioma Applied Research Foundation. B.S. has received consultant fees from Bristol Myers Squibb and speaker fees from AstraZeneca. R.B. reports research funding from the National Institutes of Health, Intuitive Surgical Foundation, Roche, Genentech, Merck, Siemens, Verastem, Gritstone, North-Pond, and Epizyme; has served as a consultant to Regeneron and on the scientific advisory board of Novocure, has equity interests in Navigation Sciences, and intellectual property interests through Brigham and Women's Hospital. B.M.B. reports research funding from the National Institutes of Health, Cancer Prevention Research Institute of Texas, and Momotaro Gene; clinical trial funding from AstraZeneca, Novartis, and Momotaro Gene; has been a consultant for AstraZeneca, is a proctor for Intuitive Surgical, and has intellectual property and equity interests in a start-up surgical device company, Bayou Surgical. Funding Information: R.T.R. reports research support from the National Institutes of Health and the American Association for Thoracic Surgery ; nonremunerated board of director of the Mesothelioma Applied Research Foundation; and was retained to provide expert opinion. A.S.M. reports research support from Novartis and Verily ; remuneration to his institution for participation on advisory boards for AbbVie, AstraZeneca, Bristol Myers Squibb, Genentech, and Janssen; travel support and payment from Shanghai Roche Pharmaceuticals Ltd ; and is a nonremunerated director of the Mesothelioma Applied Research Foundation. B.S. has received consultant fees from Bristol Myers Squibb and speaker fees from AstraZeneca. R.B. reports research funding from the National Institutes of Health , Intuitive Surgical Foundation , Roche , Genentech , Merck , Siemens , Verastem , Gritstone , North-Pond , and Epizyme ; has served as a consultant to Regeneron and on the scientific advisory board of Novocure, has equity interests in Navigation Sciences, and intellectual property interests through Brigham and Women's Hospital. B.M.B. reports research funding from the National Institutes of Health , Cancer Prevention Research Institute of Texas , and Momotaro Gene ; clinical trial funding from AstraZeneca , Novartis , and Momotaro Gene ; has been a consultant for AstraZeneca, is a proctor for Intuitive Surgical, and has intellectual property and equity interests in a start-up surgical device company, Bayou Surgical.

PY - 2023/1

Y1 - 2023/1

KW - checkpoint blockade

KW - checkpoint inhibitor

KW - immunotherapy

KW - ipilimumab

KW - mesothelioma

KW - nivolumab

KW - pleura

UR - http://www.scopus.com/inward/record.url?scp=85125319857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125319857&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2022.01.020

DO - 10.1016/j.jtcvs.2022.01.020

M3 - Editorial

C2 - 35221030

AN - SCOPUS:85125319857

SN - 0022-5223

VL - 165

SP - 364

EP - 368

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

IS - 1

ER -

Checkpoint blockade in unresectable pleural mesothelioma: Event horizon for multimodal therapy

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this